Study Showing Children and their Parents Overwhelmingly Prefer Norditropin(R) Cartridge (Somatropin [rDNA Origin] Injection) and NordiPen(R) Delivery System Presented at Pediatric Endocrinology Nursing Society Meeting

Apr 27, 2001, 01:00 ET from Novo Nordisk

    SAN DIEGO, April 27 /PRNewswire/ -- A study showing that between 71% to
 100% of children and their parents preferred Norditropin(R) cartridge and
 NordiPen(R) over three other growth hormone formulations was presented at the
 Pediatric Endocrinology Nursing Society (PENS) 14th Annual Conference.(1)
 The parents chose the premixed, ready-to-use Norditropin cartridge and
 NordiPen over three other formulations and their respective delivery systems
 with regard to ease of preparation, dosing and administration.
     Pediatric endocrinologist and Director of Growth Hormone Clinical Research
 at Novo Nordisk Pharmaceuticals, Inc. (NNPI), George Bright, M.D., said, "This
 trial demonstrated that children and their families preferred to give growth
 hormone injections with Norditropin cartridge and NordiPen.  We expect this
 overwhelming preference to improve patient and parent compliance with daily
 injections, thus addressing one of the most significant roadblocks to
 successful therapy."
     Clinical experience indicates beneficial effects of growth hormone
 treatment are influenced by dosing frequency.(2)  "As compliance improves, one
 can expect improved treatment outcomes," said Dr. Bright.
     Martin Soeters, president of NNPI, said, "Novo Nordisk is committed to
 developing innovative products that make people's lives easier.  We are deeply
 gratified that this study proves we are fulfilling that vision with our
 Norditopin family of growth hormone products."
 
     Norditropin Cartridge/NordiPen Basics
     The NordiPen companion pen delivery system is designed for simple, easy
 and accurate dosing of Novo Nordisk liquid growth hormone.  NordiPen is used
 with NovoFine(R) 30 disposable needles.  NovoFine needles benefit from thin
 wall technology, which allows for thinner needles with a wider bore than
 standard needles, resulting in less discomfort during injection.
     Norditropin cartridge is the first premixed growth hormone with a
 dedicated pen delivery system and is indicated for treatment of growth failure
 due to growth hormone deficiency in children.  The cartridges contain liquid
 Norditropin, making reconstitution unnecessary.  The Norditropin cartridge has
 a 15 mg/1.5mL capacity, which is suitable for use by all patients diagnosed
 with growth hormone insufficiency.
     Currently, more than 18,000 children are being treated in the U.S. for
 growth hormone insufficiency, which may cause short stature, reduced muscle
 and soft tissue mass and altered nutrient metabolism.
 
     Full prescribing information for Norditropin Cartridges is available by
 contacting the manufacturer or by visiting http://www.novonordisk-us.com .
 
     NovoFine, Norditropin, and NordiPen are registered trademarks of Novo
 Nordisk A/S.
 
      References:
      (1) Shine B, Musial W, Owens L, et al.  An open label, randomized,
          crossover, patient/parent, preference trial of Norditropin(R)
          cartridge versus Humatrope(R), Nutropin-AQ(R), and Genotropin(R) in
          children treated  with growth hormone.  Presented at:  Pediatric
          Endocrinology Nursing Society (PENS) 14th Annual Conference.  San
          Diego: April 2001.
 
      (2) Smith SL, et al.  Contribution of dose and frequency of
          administration to the therapeutic effect of growth hormone.  Arch Dis
          Child.  1988; 63:491-94.
 
     Novo Nordisk is a focused healthcare company and the world leader in
 diabetes care.  In addition, Novo Nordisk has a leading position within areas
 such as coagulation disorders, growth disorders and hormone replacement
 therapy.  Novo Nordisk manufactures and markets pharmaceutical products and
 services that make a significant difference to patients, the medical
 profession and society. With headquarters in Denmark, Novo Nordisk employs
 approximately 14,000 people in 68 countries and markets its products in 179
 countries.  For further company information visit http://www.novonordisk.com .
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X08563313
 
 

SOURCE Novo Nordisk
    SAN DIEGO, April 27 /PRNewswire/ -- A study showing that between 71% to
 100% of children and their parents preferred Norditropin(R) cartridge and
 NordiPen(R) over three other growth hormone formulations was presented at the
 Pediatric Endocrinology Nursing Society (PENS) 14th Annual Conference.(1)
 The parents chose the premixed, ready-to-use Norditropin cartridge and
 NordiPen over three other formulations and their respective delivery systems
 with regard to ease of preparation, dosing and administration.
     Pediatric endocrinologist and Director of Growth Hormone Clinical Research
 at Novo Nordisk Pharmaceuticals, Inc. (NNPI), George Bright, M.D., said, "This
 trial demonstrated that children and their families preferred to give growth
 hormone injections with Norditropin cartridge and NordiPen.  We expect this
 overwhelming preference to improve patient and parent compliance with daily
 injections, thus addressing one of the most significant roadblocks to
 successful therapy."
     Clinical experience indicates beneficial effects of growth hormone
 treatment are influenced by dosing frequency.(2)  "As compliance improves, one
 can expect improved treatment outcomes," said Dr. Bright.
     Martin Soeters, president of NNPI, said, "Novo Nordisk is committed to
 developing innovative products that make people's lives easier.  We are deeply
 gratified that this study proves we are fulfilling that vision with our
 Norditopin family of growth hormone products."
 
     Norditropin Cartridge/NordiPen Basics
     The NordiPen companion pen delivery system is designed for simple, easy
 and accurate dosing of Novo Nordisk liquid growth hormone.  NordiPen is used
 with NovoFine(R) 30 disposable needles.  NovoFine needles benefit from thin
 wall technology, which allows for thinner needles with a wider bore than
 standard needles, resulting in less discomfort during injection.
     Norditropin cartridge is the first premixed growth hormone with a
 dedicated pen delivery system and is indicated for treatment of growth failure
 due to growth hormone deficiency in children.  The cartridges contain liquid
 Norditropin, making reconstitution unnecessary.  The Norditropin cartridge has
 a 15 mg/1.5mL capacity, which is suitable for use by all patients diagnosed
 with growth hormone insufficiency.
     Currently, more than 18,000 children are being treated in the U.S. for
 growth hormone insufficiency, which may cause short stature, reduced muscle
 and soft tissue mass and altered nutrient metabolism.
 
     Full prescribing information for Norditropin Cartridges is available by
 contacting the manufacturer or by visiting http://www.novonordisk-us.com .
 
     NovoFine, Norditropin, and NordiPen are registered trademarks of Novo
 Nordisk A/S.
 
      References:
      (1) Shine B, Musial W, Owens L, et al.  An open label, randomized,
          crossover, patient/parent, preference trial of Norditropin(R)
          cartridge versus Humatrope(R), Nutropin-AQ(R), and Genotropin(R) in
          children treated  with growth hormone.  Presented at:  Pediatric
          Endocrinology Nursing Society (PENS) 14th Annual Conference.  San
          Diego: April 2001.
 
      (2) Smith SL, et al.  Contribution of dose and frequency of
          administration to the therapeutic effect of growth hormone.  Arch Dis
          Child.  1988; 63:491-94.
 
     Novo Nordisk is a focused healthcare company and the world leader in
 diabetes care.  In addition, Novo Nordisk has a leading position within areas
 such as coagulation disorders, growth disorders and hormone replacement
 therapy.  Novo Nordisk manufactures and markets pharmaceutical products and
 services that make a significant difference to patients, the medical
 profession and society. With headquarters in Denmark, Novo Nordisk employs
 approximately 14,000 people in 68 countries and markets its products in 179
 countries.  For further company information visit http://www.novonordisk.com .
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X08563313
 
 SOURCE  Novo Nordisk